Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

A Washington jury on Tuesday ordered Bayer to pay $100 million to four people who say they were sickened by toxic chemicals ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

2025--(BUSINESS WIRE)--On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple ...

The pharmaceutical company’s latest partnership with Incremental and Skai drove a 32% boost in iROI, delivering nearly a third more sales per ad dollar.

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Bayer's Global Capability Centre in Hyderabad contributes to R&D, data science, and AI-driven healthcare solutions, ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco ... has recently been initiated (outside of the US). The open-label, first-in-human, dose escalation study will ...

and President of Bayer’s Pharmaceuticals Division. "Our new operating model is visibly becoming a key enabler to drive growth and efficiency gains." Topline improved and poised for future growth Bayer ...